APA (7th ed.) Citation

CAL, T., D, T., M, D., K, L., F, S., RA, P., . . . D, T. (2026). Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity. Blood, 147(14), 1611. https://doi.org/10.1182/blood.2024027897

Chicago Style (17th ed.) Citation

CAL, Thompson-Peach, et al. "Ultraprecision Therapy for Type 1 Vs Type 2 CALR+ MPN by Dual Epitope Targeting That Restores Ruxolitinib Sensitivity." Blood 147, no. 14 (2026): 1611. https://doi.org/10.1182/blood.2024027897.

MLA (9th ed.) Citation

CAL, Thompson-Peach, et al. "Ultraprecision Therapy for Type 1 Vs Type 2 CALR+ MPN by Dual Epitope Targeting That Restores Ruxolitinib Sensitivity." Blood, vol. 147, no. 14, 2026, p. 1611, https://doi.org/10.1182/blood.2024027897.